Search Femetric

Search peptides, goals, protocols and references

Weight ManagementAppetiteGlucose / InsulinFat Loss

GLP-1 receptor agonist

Liraglutide

An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.

FEMETRIC RECORD · PUBLICLiraglutide
Weight ManagementAppetiteGlucose / Insulin
Status
Approved
Related
3
Sources
1
UPDATED 2026-09-13
01

Protocol references

SOURCE-LINKED

PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYNew England Journal of Medicine, 2015Verified 2026-09-13
View primary source
04

How this works

Liraglutide activates the GLP-1 receptor. Its daily pharmacologic and trial structure differs from longer-acting weekly GLP-1 receptor agonists.

Mechanism summaries are stored with field-level source provenance for editorial audit.
07

Related research goals

08

Related peptides

01PEPTIDE

Semaglutide

An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.

Weight ManagementAppetiteGlucose / Insulin
02PEPTIDE

Tirzepatide

An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.

Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE

Cagrilintide

An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.

Weight ManagementAppetiteFat Loss
09

Compare Liraglutide

11

References

01
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine · 2015 · DOI 10.1056/NEJMoa1411892
CLINICAL TRIAL
Page reviewed: 2026-09-13References updated: 2026-09-13

THE SIGNAL

The research worth knowing.

Peptides, emerging performance research and new Femetric tools.
NEXT RESEARCH ACTION
Was this useful?